Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments

The clearance route and the absolute values for hepatic and renal clearance of drugs are important criteria for the selection of drug candidates. Based on pharmacokinetic theory, by assuming that uptake is the rate-determining process for the biliary excretion of drugs, organ intrinsic clearance should be simply estimated by the intrinsic uptake. In this study, to investigate whether organ clearance can be predicted from the in vitro uptake activity, we performed uptake experiments using isolated hepatocytes and kidney slices, integration plot analyses, and in vivo pharmacokinetic studies using 12 barely metabolized drugs in rats. The in vivo hepatic and renal clearance could be approximated by uptake clearance estimated from integration plot analyses, except for the renal clearance of some drugs that was relatively small. The comparison of intrinsic uptake clearance from in vitro experiments and integration plot studies revealed that in vivo hepatic uptake was well explained by uptake into isolated hepatocytes, whereas in kidney, in vivo uptake clearance was 10 to 100 times that in kidney slices and a scaling factor is required for its prediction from in vitro experiments. The organ clearance and the fraction excreted into urine could be predicted from in vitro studies except for drugs whose renal clearance was relatively small. This study suggests that the uptake process is the determining factor for organ clearance of minimally metabolized drugs, and uptake assays using isolated hepatocytes and kidney slices are useful for evaluating the uptake clearance.

[1]  A. Tsuji Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy , 2006, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  Jing-Tao Wu,et al.  Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. , 2005, Current topics in medicinal chemistry.

[3]  K. Brouwer,et al.  Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse Livers , 2008, Drug Metabolism and Disposition.

[4]  H. Kusuhara,et al.  Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. , 2002, The Journal of pharmacology and experimental therapeutics.

[5]  Yuichi Sugiyama,et al.  Contribution of Organic Anion Transporters to the Renal Uptake of Anionic Compounds and Nucleoside Derivatives in Rat , 2003, Journal of Pharmacology and Experimental Therapeutics.

[6]  M. Fromm,et al.  Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  Y. Sugiyama,et al.  Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). , 1997, The Journal of pharmacology and experimental therapeutics.

[8]  Y. Sugiyama,et al.  Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. , 1993, The American journal of physiology.

[9]  D. Putt,et al.  Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. , 2008, Toxicology.

[10]  M. Rowland,et al.  Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model , 1986, The Journal of pharmacy and pharmacology.

[11]  D. Putt,et al.  Membrane transport function in primary cultures of human proximal tubular cells. , 2006, Toxicology.

[12]  Y. Sugiyama,et al.  Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. , 1998, The Journal of pharmacology and experimental therapeutics.

[13]  Y. Sugiyama,et al.  Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[14]  Roberts Sa,et al.  High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. , 2001 .

[15]  K. Maeda,et al.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  S. Higuchi,et al.  Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy , 2006, Expert opinion on drug metabolism & toxicology.

[17]  S. Roberts,et al.  High-throughput screening approaches for investigating drug metabolism and pharmacokinetics , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  T. Lynch,et al.  The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. , 2007, American family physician.

[19]  Y. Sugiyama,et al.  Comparison of the Hepatic Uptake Clearances of Fifteen Drugs with a Wide Range of Membrane Permeabilities in Isolated Rat Hepatocytes and Perfused Rat Livers , 1993, Pharmaceutical Research.

[20]  Diana Kazolias,et al.  Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.

[21]  K. Maeda,et al.  Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  Yuichi Sugiyama,et al.  Quantitative Evaluation of the Drug-Drug Interactions between Methotrexate and Nonsteroidal Anti-Inflammatory Drugs in the Renal Uptake Process Based on the Contribution of Organic Anion Transporters and Reduced Folate Carrier , 2004, Journal of Pharmacology and Experimental Therapeutics.

[23]  Y. Sugiyama,et al.  Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats. , 2002, American journal of physiology. Endocrinology and metabolism.

[24]  H. Kusuhara,et al.  Gender Difference in the Urinary Excretion of Organic Anions in Rats , 2002, Journal of Pharmacology and Experimental Therapeutics.

[25]  H. Takikawa,et al.  Effects of colchicine and phenothiazine on biliary excretion of organic anions in rats , 1998, Journal of gastroenterology and hepatology.

[26]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[27]  K. Maeda,et al.  Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine , 2008, Molecular Pharmacology.

[28]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[30]  Yuichi Sugiyama,et al.  Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.

[31]  H. Kusuhara,et al.  Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) , 2008, Journal of Pharmacology and Experimental Therapeutics.

[32]  S. Furuta,et al.  Pharmacokinetics of Temocapril and Enalapril in Patients with Various Degrees of Renal Insufficiency , 1993, Clinical pharmacokinetics.

[33]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[34]  Y. Sugiyama,et al.  Apical/Basolateral Surface Expression of Drug Transporters and its Role in Vectorial Drug Transport , 2005, Pharmaceutical Research.